[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,127,0,25,[9,41,69,89,115,139,159,185,208,232,260,279,306,329,355,380,405,461,486,508,574,597,625,648,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651056","vividflo-system-validation-study-100651056",false,"NCT07754201","VividFlo System Validation Study","A Prospective Evaluation of the Safety and Effectiveness of VividFlo Implantation Using a Partial-Thickness Scleral Flap Technique and The VividFlo System.","Inclusion Criteria:\n\n1. Age, Capacity \\& Consent:\n\n   1. Be 18 years of age or older.\n   2. Be able to understand all study instructions, and willing to comply with all study procedures and the visit schedule.\n   3. Provide written, informed consent to participate.\n2. Glaucoma in the study eye, meeting all of the following requirements:\n\n   1. Diagnosed by the investigator, based upon untreated intraocular pressure, disc appearance and visual field abnormalities.\n   2. The glaucoma type is one of:\n\n   i. Primary open angle glaucoma (POAG). ii. Chronic angle closure glaucoma (CACG) where the eye is pseudophakic. iii. Mixed mechanism POAG\u002FCACG where a laser iridotomy has previously been performed.\n\n   iv. Pigmentary open angle glaucoma. v. Exfoliation open angle glaucoma. vi. Neovascular glaucoma that is treated and regressed\u002Fquiescent. c. Glaucoma drainage surgery is indicated due to failure of previous treatment (the glaucoma is 'refractory'), with failure of maximum tolerated medical therapy and one of the following circumstances: i. No previous glaucoma surgery. ii. Prior trabecular bypass (using iStents or Hydrus) or cilioablation. iii. Failure of one prior glaucoma drainage operation (that is one of trabeculectomy, deep sclerectomy or Xen).\n\n   d. The mean diurnal IOP at Baseline is greater than or equal to 20 mmHg and less than or equal to 40 mmHg.\n\n   e. The conjunctiva in the target quadrant is suitable for glaucoma surgery.\n\n   Key Exclusion Criteria:\n   * Advanced glaucomatous optic neuropathy that threatens fixation, in the opinion of the investigator.\n   * The glaucoma type is any of the following:\n\n     1. Acute Angle Closure Glaucoma (AACG).\n     2. Chronic Angle Closure Glaucoma (CACG) where the eye is phakic.\n     3. Congenital glaucoma. Juvenile Open-Angle Glaucoma or Congenital Glaucoma.\n     4. Secondary glaucoma of any type not specified in the inclusion criteria, including inflammatory glaucoma, active neovascular glaucoma, traumatic glaucoma, Iridocorneal Endothelial (ICE) Syndrome, and silicone oil induced glaucoma.\n   * Previous glaucoma surgery with:\n\n     1. A tube-and-plate glaucoma drainage implant (GDI, e.g. Molteno, Baerveldt, Paul).\n     2. A suprachoroidal implant.\n     3. Multiple previous operations for glaucoma.\n     4. Glaucoma surgery within 3 months of screening.\n   * Cataract surgery or any other ocular surgery is indicated at the time of study intervention or is anticipated to be required during the study duration.\n   * Conjunctival scarring or pterygium in the target quadrant.\n   * Severe dry eye disease.\n   * Significant corneal disease.\n   * Accurate measurement of baseline central corneal endothelial density is not possible.\n   * Any treatment or condition that, in the opinion of the investigator, may impact corneal endothelial cell density beyond expected age \\& disease-related decline.\n   * Significant retinal or posterior segment pathology, including but not limited to:\n\n     1. Active and clinically significant diabetic retinopathy.\n     2. Active choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, proliferative retinopathy.\n     3. Intraocular silicone oil.\n     4. Presence of a scleral buckle.\n   * Vitreous present in the anterior chamber.\n   * Active uveitis or clinically significant infection or inflammation.\n   * Unfit for surgery under local anaesthetic.\n   * Any uncontrolled systemic disease.\n   * The participant is pregnant, breastfeeding, or cannot guarantee they will not conceive or donate sperm or eggs during the study.\n   * Significant risk of bleeding.\n   * Any other clinical or social reason that, in the opinion of the investigator, means standard surgical treatment for glaucoma would be considered safer than participation in the study.","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a 10-participant study to assess the VividFlo System and surgical implantation using a modified technique.",[27],"Glaucoma","NOT_YET_RECRUITING","2026-08-16",{"date":31,"type":32},"2026-08-18","ACTUAL",{"date":34,"type":21},"2026-08-10",{"date":36,"type":21},"2028-03",{"name":38,"class":39},"VividWhite Pty Ltd","INDUSTRY",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100652190","phase-1-a-study-about-the-safety-of-asp2767-and-whether-it-helps-people-with-glaucoma-related-optic-nerve-damage-100652190","NCT07770685","A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage","A Phase 1, Multicenter, Open-Label, Ascending-Dose and Phase 2, Randomized, Double-Masked, Sham-Controlled, Clinical Study to Evaluate the Safety and Efficacy of ASP2767 in Participants With Optic Neuropathy Due to Glaucoma","Inclusion Criteria:\n\n* Participant agrees not to participate in another interventional study until the 52-week visit has been completed.\n* Participant is able and willing to comply with the study requirements and capable of completing the assessments, including all scheduled visits.\n* Participant has open-angle glaucoma (OAG) defined as rate of MD ≤ -0.5 dB\u002Fyear and consisting of all of the following:\n\n  * Presence of glaucomatous VF defects in the study eye with corresponding damage to the optic nerve head (ONH) (confirmed by an independent central image reading center at screening)\n  * An open iridocorneal drainage angle observed on gonioscopy (Shaffer grade ≥ 3)\n  * Moderate to advanced VF loss, assessed by standard automated perimetry, and confirmed by the central image reading center and in the study eye:\n  * Phase 1 - Dose-Escalation part: advanced VF loss, defined as MD between -12 and -20 dB\n  * Phase 2 - Dose-Expansion part: moderate to advanced VF loss, defined as MD between -6 and -20 dB\n  * At least 3 reliable VF tests (≤ 33% FLs and ≤ 15% FP) within the preceding 84 months, confirmed by the central image reading center, and excluding fields obtained before incisional glaucoma or cataract surgeries\n  * Evidence of VF function in at least 1 quadrant in the study eye\n  * BCVA ≥ 20\u002F200 (≥ 35 ETDRS letters) at screening and confirmed on day 1 in the study eye\n  * At least 3 consecutive reliable optical coherence tomography (OCT) scans (peripapillary RNFL, GCC\u002Fmacula) in the study eye within the preceding 84 months, confirmed by the central image reading center.\n* Participant must have an IOP ≤ 21 mmHg on current therapy in the study eye (or participant's IOP is considered well controlled and will not require any additional medical or surgical treatment in the next 12 months).\n* Female participant is not pregnant and at least 1 of the following conditions apply:\n\n  * Not a women of childbearing potential (WOCBP) o. WOCBP who has a negative serum pregnancy test at screening, or urine pregnancy test on day 1, agrees to follow the contraceptive guidance from the time of informed consent.\n* Female participant must not be breastfeeding or lactating starting at screening and throughout the study period.\n* Female participant must not donate ova starting at first administration of study intervention and throughout the study period.\n* Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period.\n* Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period.\n* Male participant must not donate sperm during the treatment period (up to week 52).\n\nExclusion Criteria:\n\n* Participant has other optic nerve or retinal degenerative disease-causing vision loss, irrespective of whether it is currently treated or untreated.\n* Participant has other known or suspected molecular diagnosis of macular, retinal, or optic nerve disease (e.g., pathogenic mutations in other genes) that could confound the interpretation of the outcome of the study, that could cause a concomitant retinal disease and\u002For point to an alternate etiology of macular or optic nerve disease.\n* Participant has visually significant cataract in the study eye.\n* Participant has active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis (mild stable blepharitis is permitted).\n* Participant is expected to require a change in IOP-lowering treatment within 6 weeks of screening and\u002For is anticipated to require a change in IOP-lowering treatment during the study in the study eye.\n* Participant has history of\n\n  * closed or narrow angle (Shaffer grade ≤ 2), pigment dispersion, uveitic glaucoma, or congenital glaucoma\n  * cyclophotocoagulation laser treatment for glaucoma in the study eye\n  * ocular herpetic disease (including herpes simplex and zoster viruses) or disseminated\u002Fvisceral herpes zoster infection\n  * allergy to fluorescein or povidone iodine\n  * history of steroid response (historic evidence of IOP increase with corticosteroid use)\n* Participant has presence of IOI (≥ trace anterior chamber \\[AC\\] cell or flare), has active or has a history of idiopathic or autoimmune-associated uveitis in either eye.\n* Participant has evidence of corneal opacification or lack of optical clarity in the study eye.\n* Participant has refractive error greater than 8 diopters of spherical equivalent at screening in the study eye.\n* Participant has choroidal neovascularization, central serous retinopathy, or any other type of retinal degeneration\u002Fdiseases that may interfere with the study procedures, evaluations and outcome assessments.\n* Participant has undergone any laser or intraocular surgery (i.e., cataract surgery or minimally invasive glaucoma surgery) in the study eye within 12 weeks and\u002For yttrium aluminum garnet capsulotomy within 4 weeks prior to screening.\n* Participant has a history of vitrectomy surgery in the study eye.\n* Participant has a history of, or currently has, optic neuropathy not due to glaucoma, including traumatic or anterior ischemic optic neuropathy.\n* Participant has presence of any other concurrent ocular disease in the study eye that would affect or confound study outcomes.\n* Participant has any of the following medical conditions\n\n  * diabetes mellitus hemoglobin A1c (HbA1c) value of \\> 7% at screening, with the following exception: If the HbA1c value is \\> 7% and the participant has a normal creatinine, has no diabetic retinopathy, or diabetic macular edema, then the participant may be enrolled at the discretion of the investigator after consultation with the medical monitor\n  * uncontrolled hypertension defined as an average systolic blood pressure \\> 160 mmHg or an average diastolic blood pressure \\> 100 mmHg (second set of measurements is permitted if the first average exceeds the values during the same visit). Additional repeat measurement may be obtained within the screening window\n  * history of malignancy other than basal cell carcinoma, unless it was treated successfully at least 2 years prior to inclusion in the study\n  * history of multiple sclerosis or other severe autoimmune conditions\n  * history of uncontrolled hepatitis, pancreatitis, cirrhosis, asthma, liver\u002Fkidney\u002Fheart failure, or uncontrolled thyroid disease or intracranial hypertension\n* Participant is currently receiving systemic steroids (other than those related to the study), chemotherapy, immunosuppressive medications, monoclonal antibodies, or glucagon-like peptide-1 treatment.\n* Participant is currently using drugs with known ocular toxicity or confounding effects on VF assessments (including but not limited to hydroxychloroquine \\[Plaquenil\\], chloroquine, amiodarone, ethambutol, isoniazid, anticholinergics, sulfonamides \\[including TMP-SMX\u002FBactrim\\], and linezolid) unless these were stopped prior to screening and all possible ocular reactions were completely resolved without sequelae.\n* Participant has received any prior treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or prior IVT treatment for any indication in either eye that may be considered to potentially interfere with the study participation or its conduction.\n* Participant is currently participating in an interventional clinical study or has received an investigational agent by ocular or systemic administration within 3 months or 5 half-lives, whichever is longer prior to the screening.\n* Participant has any severe acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality may interfere with the study procedures, evaluation and outcome assessments and would make the participant unsuitable for study participation.",{"count":49,"type":21},156,[51,52],"PHASE1","PHASE2","Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include eye drops, laser treatment, and surgery that help lower eye pressure. However, they do not work for everyone, and the disease may continue to worsen over time. Researchers are looking for better ways to treat open-angle glaucoma.\n\nThis is an early development study of ASP2767 in people with open-angle glaucoma. In this study, ASP2767 will be given to humans for the first time. ASP2767 is a type of treatment called gene therapy. Gene therapy uses a tool called a vector. In this study a harmless virus is used as the vector. The vector delivers genes into specific parts of the body like the eyes.\n\nOnce in the eyes these genes help nerve cells in the retina make proteins. These proteins are designed to protect the nerves in the eyes and may help slow down or prevent vision loss.\n\nThe main aims of the study are to check the safety of ASP2767 in people with open-angle glaucoma, how well they tolerate it, and to find the highest dose of ASP2767 people can safely receive. In addition, the study will also look at the effect of ASP2767 on vision in people with open-angle glaucoma.\n\nThe study has 2 phases. In both phases of the study, ASP2767 will be given as a single injection into one eye only.\n\nIn phase 1, small groups of people with open-angle glaucoma will receive ASP2767 starting with lower doses and increasing to higher doses in later groups. The people in the study will also receive prophylactic medicines which will help reduce the risk of inflammation after receiving the ASP2767 injection. Phase 1 is an open-label study. This means that people in the study and the researchers will know which treatment people are getting. Any medical problems people have at each dose level in this study will be recorded. This will help find the highest dose of ASP2767 that people can safely receive, which will also be used in phase 2.\n\nIn phase 2, another larger group of people with open-angle glaucoma will be randomly placed in 1 of 3 groups of equal size. This means each person will have an equal chance of being placed in any of the 3 groups. They will receive either the highest dose of ASP2767 that people safely received in phase 1, or a slightly lower dose of ASP2767, or a sham injection. A sham injection is a procedure that mimics the injection but does not deliver ASP2767 into the eye. To reduce the risk of inflammation due to the injection, people in the study will also receive a prophylactic medicine or placebo depending on the group they are in. The placebo will look like the prophylactic medicine and will be given in a similar way but will not have any active medicine in it. Researchers use sham injections and placebo to make sure any effect they see in people who take ASP2767 is actually caused by the drug. Phase 2 is a double-masked study, meaning neither the people in the study, nor the researchers will know who is given which treatment.\n\nAll the people in phase 1 and phase 2 will be followed up for about 1 year after receiving the treatment. After receiving their ASP2767 injection, people will visit the clinic on certain days to have health checks. They will also have their vision checked using different eye tests and will give regular blood and urine samples.",[27],[27,56,57,58,59,60],"ASP2767","Safety","Tolerability","Optic Neuropathy","Neuroprotection","2026-08-14",{"date":31,"type":32},{"date":64,"type":21},"2026-08-31",{"date":66,"type":21},"2030-07-31",{"name":68,"class":39},"Astellas Pharma Global Development, Inc.",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100652169","impact-of-meditation-on-reducing-stress-in-glaucoma-patients-an-electronic-feasibility-study-100652169","NCT07769463","Impact of Meditation on Reducing Stress in Glaucoma Patients: An Electronic Feasibility Study","Inclusion Criteria:\n\n* Diagnosed with glaucoma or suspected to have glaucoma.\n* Aged 65 and above.\n* Able to provide valid informed consent to participate in the research study.\n* Able to read and understand English.\n* No significant self-reported or physician-diagnosed mental health disorder.\n* Independent access to a computer to participate in virtual sessions.\n* Able to sit comfortably for 30 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health.\n* Willing to practice meditation at home for \\~15 minutes per day.\n\nExclusion Criteria:\n\n* Inability to provide valid informed consent.\n* Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.\n* Self-reported substance abuse or dependence within the past 3 months.\n* Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.\n* Having irreversible vision loss that prevents one from completing the questionnaires.\n* Participation in a study involving similar techniques.\n* Established meditation practice, defined as engaging in any formal meditation (e.g., mindfulness, mantra, breath-focused) more than twice per week within the past 3 months.","65 Years",{"count":77,"type":21},158,[24],"Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of meditation for potentially enhancing the QOL and reducing stress in glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm. Participants in each arm will complete online questionnaires at baseline and weeks 1, 3, 6, and 12 to collect data on health-related quality of life (HRQOL), perceived stress, and behaviour using REDCap. REDCap is an online data collection and survey tool hosted by the Office of Research Services of Lawson Research Institute. Our study can help to assess the feasibility of conducting a study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.",[27],{"date":31,"type":32},{"date":83,"type":21},"2026-11-01",{"date":85,"type":21},"2028-12-01",{"name":87,"class":88},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100652137","cross-modal-neuromodulation-to-improve-balance-and-cognition-in-older-adults-with-glaucoma-a-randomized-trial-of-cerebellar-transcranial-electrical-stimulation-100652137","NCT07771699","Cross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation","Inclusion Criteria:\n\n* Age over 55 years old;\n* Diagnosis of primary open-angle or normal-tension glaucoma with relative scotoma in both eyes;\n* Humphrey Field Analyzer visual field loss (mean deviation of ≤- 6 dB) using the 24-2 testing protocol for both eyes;\n* Best-corrected distance visual acuity of 6\u002F12 (equivalent to 0.3 logMAR) or better;\n* Cognitive functional score of 22 or above in the Montreal Cognitive Assessment -Hong Kong version (HK-MoCA).\n* Only the right-handed population will be recruited (screening by the Edinburgh Handedness Inventory).\n\nExclusion Criteria:\n\n* Have musculoskeletal disorders or neurological diseases that can affect the balance or nervous system.\n* Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participants can hear the instructions clearly during assessments and training)\n* Have any contraindications for tES","55 Years",{"count":97,"type":21},36,[24],"The goal of this clinical trial is to use different tES techniques to constantly stimulate the cerebellum in older glaucoma patients. The main questions aim to answer :\n\n1. If the different types of tES targeting the cerebellum can modulate glaucoma patients' balance function and visual-cognitive function?\n2. Which tES techniques among the two types can benefit most?\n\nParticipants will be required to receive the stimulation 15 times (3 sessions, 5 continuous days\u002Fsession, 1-week interval between each session), and complete the balance and visual-cognitive function outcome measurements before and after each session.",[27],[102,103,104,105],"balance","glaucoma","visual attention","transcranial electrical stimulation","RECRUITING","2026-08-13",{"date":31,"type":32},{"date":110,"type":32},"2026-07-01",{"date":112,"type":21},"2029-11-01",{"name":114,"class":88},"The Hong Kong Polytechnic University",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":40},"100592451","study-of-corneal-biomechanics-in-glaucoma-patients-using-brillouin-microscopy-100592451","NCT06993597","Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","Development of Robust Corneal Biomechanical Biomarkers for Glaucoma Using Brillouin Microscopy","Inclusion Criteria:\n\n\\- Age 18 years or older\n\nDiagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls)\n\nOpen angle on gonioscopy (Shaffer grade 3 or 4)\n\nBest-corrected visual acuity of 20\u002F25 or better\n\nRefractive error between +3.00 and -5.00 diopters\n\nNo prior use of topical glaucoma medications\n\nDiagnosis of:\n\nHigh Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits)\n\nNormal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits)\n\nOR age-matched control with normal optic nerve and visual fields\n\nExclusion Criteria:\n\nCorneal abnormalities or conditions interfering with Brillouin or applanation tonometry\n\nRetinal diseases affecting RNFL (e.g., macular traction)\n\nHistory of ocular surgery or laser\n\nDiagnosis of diabetes\n\nHistory of uveitis\n\nHistory of prolonged steroid use\n\nNeurodegenerative or systemic diseases (e.g., multiple sclerosis, Alzheimer's, Parkinson's, schizophrenia)\n\nUnreliable visual fields\n\nContraindications to beta blockers (e.g., bradycardia, severe pulmonary disease)\n\nModerate to severe glaucoma (per Hodapp-Anderson-Parrish criteria)\n\nHistory of contact lens use\n\nLow blood pressure",true,{"count":124,"type":21},60,"OBSERVATIONAL","This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.",[27],[103,129,130],"cornea","biomechanics","2026-08-07",{"date":34,"type":32},{"date":134,"type":32},"2025-09-01",{"date":136,"type":21},"2027-06",{"name":138,"class":88},"University of Maryland, Baltimore",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":40},"100651240","validation-of-the-artificial-intelligence-subsystem-of-the-ddart-medical-device-for-the-automated-detection-of-lesions-compatible-with-glaucoma-in-a-random-sample-of-retinal-fundus-photographs-100651240","NCT07758569","Validation of the Artificial Intelligence Subsystem of the DDART Medical Device for the Automated Detection of Lesions Compatible With Glaucoma in a Random Sample of Retinal Fundus Photographs","Validation of the Artificial Intelligence Subsystem of the DDART Medical Device for the Automated Detection of Lesions Compatible With Glaucoma in a Random Sample of Retinal Fundus Photograph","Inclusion Criteria:\n\n* Age ≥18 years. Availability of a high-resolution color fundus photograph. Confirmed diagnosis established by a specialist.\n\nExclusion Criteria:\n\n* Poor-quality images. Coexisting ocular diseases that interfere with image interpretation.",{"count":147,"type":21},2000,"Primary Objective\n\nTo validate the artificial intelligence subsystem of the DDART medical device for the automated detection of lesions compatible with glaucoma in a random sample of retinal fundus photographs.",[27],"2026-08-06",{"date":152,"type":32},"2026-08-11",{"date":154,"type":32},"2026-04-21",{"date":156,"type":21},"2027-04-19",{"name":158,"class":88},"Democritus University of Thrace",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":40},"100651008","innovative-tube-trabeculectomy-for-advanced-and-refractory-glaucoma-a-randomized-controlled-trial-100651008","NCT07755761","Innovative Tube Trabeculectomy for Advanced and Refractory Glaucoma: A Randomized Controlled Trial","A Prospective, Randomized, Controlled, Single-Center Clinical Trial to Evaluate the Efficacy and Safety of Innovative Tube Trabeculectomy Compared to Conventional Trabeculectomy in Patients With Advanced and Refractory Glaucoma","ITT-RCT","Inclusion Criteria:\n\n\\- • Diagnosis of advanced or refractory primary open-angle glaucoma (POAG) or secondary open-angle glaucoma (excluding neovascular glaucoma).\n\n* Intraocular pressure (IOP) \\> 21 mmHg despite maximal tolerated medical therapy or previous failed glaucoma surgery.\n* Best corrected visual acuity (BCVA) of 20\u002F400 or better.\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Previous incisional glaucoma surgery in the study eye (except for prior failed trabeculectomy in the refractory group).\n* Neovascular glaucoma or other forms of secondary glaucoma that may significantly impact wound healing (e.g., uveitic glaucoma).\n* Significant ocular comorbidities that may confound outcome assessment (e.g., severe corneal disease, retinal detachment).\n* Pregnancy or lactation.\n* Participation in another clinical trial within 30 days prior to enrollment.",{"count":168,"type":21},116,[24],"This study aims to compare the efficacy and safety of a novel surgical technique, Innovative Tube Trabeculectomy (ITT), against conventional trabeculectomy in patients with advanced and refractory glaucoma. ITT incorporates a unique preoperative regimen and surgical modifications, including a deep extended scleral tunnel, X-shaped non-absorbable suture, and a nasolacrimal tube implant, designed to enhance aqueous humor outflow and reduce postoperative fibrosis. Participants will be randomized to receive either ITT or conventional trabeculectomy and followed for 12 months to assess intraocular pressure control, medication use, complication rates, and bleb morphology.",[27,172,173],"Trabeculectomy","Innovative Procedures",[103,175,176],"innovative","tube trabeculectomy","2026-08-05",{"date":34,"type":32},{"date":180,"type":32},"2026-08-01",{"date":182,"type":21},"2028-08-01",{"name":184,"class":88},"Benha University",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":122,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":40},"100526805","optimize-pediatric-oct-imaging-100526805","NCT06139523","Optimize Pediatric OCT Imaging","Optimize Pediatric OCT (Optical Coherence Tomography) Imaging: a Pilot Study","Inclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age\n* Healthy adult volunteers without known ocular issues other than refractive error\n* Pregnancy Reasonably Excluded Guide (PREG) evaluation on women of childbearing potential\n* Group 2 - Pediatric participants\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent\u002Flegal guardian\n* Parent\u002Flegal guardian is able and willing to consent to study participation\n* Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center\n\nExclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Students or employees under direct supervision of the investigators\n* Subjects with prior problems with pupil dilation\n* Pregnant woman if receiving dilating drops\n* Group 2 - Pediatric participants\n* Parent\u002Flegal guardian unwilling or unable to provide consent\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)",{"count":193,"type":21},30,"Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina.\n\nThe investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).",[196,27,197],"Retinal Disease","Optic Nerve Diseases",[199],"Optical Coherence Tomography (OCT)","2026-08-03",{"date":177,"type":32},{"date":203,"type":32},"2024-01-24",{"date":205,"type":21},"2027-12",{"name":207,"class":88},"Duke University",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":40},"100649809","this-study-examines-whether-personality-traits-influence-the-frequency-or-severity-of-ocular-adverse-effects-reported-by-patients-using-glaucoma-medications-the-findings-may-identify-patients-at-greater-risk-of-intolerance-and-support-more-personalized-treatment-and-counselling-100649809","NCT07739784","This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.","Personality Traits and Their Relation to Ocular Adverse Effects From Glaucoma Medications","Adverse Events","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of glaucoma.\n* Current or previous treatment with one or more glaucoma medications.\n* Able to provide informed consent.\n* Able to complete the study questionnaires in English or French.\n\nExclusion Criteria:\n\n* Uncontrolled anxiety or depression that was present before glaucoma medication treatment began.\n* Unable to provide informed consent.\n* Unable to complete the study questionnaires in English or French.",{"count":217,"type":21},352,"The goal of this observational study is to learn whether personality traits are related to eye side effects from glaucoma medications in adults who currently use or previously used these medications.\n\nThe main questions this study aims to answer are:\n\nAre certain personality traits associated with the occurrence or severity of eye side effects from glaucoma medications? Do personality traits differ between people who experience these side effects and those who do not?\n\nParticipants will complete a questionnaire that measures five personality traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism. They will also provide basic demographic information. The researchers will review participants' medical records to collect information about their glaucoma medications and any related eye side effects, including the type and frequency of side effects and whether treatment was changed because of them.\n\nParticipation involves one session lasting approximately 30 minutes. Questionnaires may be completed securely online or in person at the clinic. The study will include approximately 352 adults. No treatment will be assigned or changed as part of this study.",[27],[221,222,103],"adverse events","Personality traits","2026-07-30",{"date":225,"type":32},"2026-07-31",{"date":227,"type":32},"2026-02-25",{"date":229,"type":21},"2027-08-01",{"name":231,"class":88},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100649383","phase-4-baerveldt-versus-paul-study-100649383","NCT07733453","Baerveldt Versus Paul Study","The Baerveldt Versus Paul (BvP) Study: a Registry-based Randomised Controlled Trial","BvP","Inclusion Criteria:\n\n1. Age ≥ 18 years of age\n2. Glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 16 mm Hg.\n3. An aqueous shunt implant as planned surgical procedure\n4. A diagnosis of ocular hypertension, primary open angle glaucoma, primary angle closure glaucoma, or secondary glaucoma.\n\nExclusion Criteria:\n\n1. Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits.\n2. Pregnant or nursing women.\n3. No light perception vision.\n4. Uveitis secondary to Juvenile Idiopathic Arthritis\n5. Previous cyclodestructive procedure or previous aqueous shunt device implanted in the same eye\n6. Supero-temporal buckling or other external impediment to supero-temporal aqueous shunt implantation\n7. Silicone oil-filled eyes or sufficient residual intraocular silicone oil to preclude supero-temporal aqueous shunt implantation\n8. Vitreous present in the anterior chamber, sufficient to require a vitrectomy at the time of surgery\n9. Condition with high episcleral pressure, such as Sturge-Weber or nanophthalmos\n10. Acute trauma (within 3 months)\n11. Need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for additional ocular surgery.",{"count":241,"type":21},150,[243],"PHASE4","The Baerveldt Versus Paul (BvP) Study is a Registry-based Randomised Controlled Trial, Comparing the Baerveldt Glaucoma Implant (BGI) and the Paul Glaucoma Implant (PGI). Participants will Include patients requiring aqueous shunt surgery for control of intraocular pressure and glaucoma.\n\nThe objective of this study is to compare the long-term safety and effectiveness of placement of a BGI and PGI for patients who are undergoing aqueous shunt implant surgery. Patients who qualify for the study are randomized to receive either a BGI or PGI aqueous shunt.",[27],[247,248,249,250,251],"aqueous shunt surgery","glaucoma drainage device","glaucoma filtration surgery","Baerveldt Glaucoma Implant","Paul Glaucoma Implant",{"date":200,"type":32},{"date":254,"type":21},"2026-10-12",{"date":256,"type":21},"2033-04",{"name":258,"class":88},"University of Sydney",4,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":40},"100649288","the-effectiveness-of-home-based-circuit-training-on-eye-pressure-and-eye-nerve-structures-in-patients-with-glaucoma-100649288","NCT07733388","The Effectiveness Of Home-Based Circuit Training On Eye Pressure And Eye Nerve Structures In Patients With Glaucoma","The Effectiveness Of Home-Based Circuit Training On Intraocular Pressure, Retinal Nerve Fiber Layers And Choroidal Thickness In Patients With Glaucoma","Inclusion Criteria:\n\n* Age ≥ 18 - 70 years old\n* Known case of POAG, PACG, JOAG, NTG\n* Phakic without visually significant cataract\n* Pseudophakic for more than 3 months prior to recruitment\n* Achieved target IOP\n* Physically not performing routine exercises\n\nExclusion Criteria:\n\n* Bilateral eye visual acuity of less than 6\u002F60\n* Bilateral eye visual field defect of less than 10 degrees from fixation\n* Patient with media opacities that affect the reliability of OCT measurements such as cornea opacity, dense cataract with Lens opacification classification system (LOCS III) of more than grade 2, vitreous haemorrhage\n* Patient who underwent intraocular surgery (other than uncomplicated cataract surgery), including anti-vascular endothelial growth factor injection within past 6 months\n* Ocular disease such as cornea ulcer, uveitis, age-related macula degeneration\n* Physical disabilities such as stroke, limbs amputation\n* Uncontrolled systemic diseases eg diabetes, hypertension\n* Morbid Obesity (BMI \\> 40)\n* Dementia or any psychiatric diseases\n* Smoking","70 Years",{"count":124,"type":21},[24],"The goal of this randomised control trial is to learn about the effect of home based circuit training on patients with primary glaucoma.\n\nThe main questions to answer are:\n\n1. Is there any difference of intraocular pressure (IOP) in patient with primary glaucoma after 6 weeks and 12 weeks who is performing home-based circuit training compared to patient not performing home-based circuit training?\n2. Is there any difference of retina nerve fibre layer in patient with primary glaucoma after 6 weeks and 12 weeks who is performing home-based circuit training compared to patient not performing home-based circuit training?\n3. Is there any difference of choroidal thickness layer in patient with primary glaucoma after 6 weeks and 12 weeks who is performing home-based circuit training compared to patient not performing home-based circuit training?\n\nResearchers will compare patients with primary glaucoma who are performing home-based circuit training and not performing home-based circuit training to see if any affect to intraocular pressure, retina nerve fibre layer and choroidal thickness.",[27],"2026-07-29",{"date":223,"type":32},{"date":180,"type":21},{"date":276,"type":21},"2027-12-01",{"name":278,"class":88},"Universiti Sains Malaysia",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":286,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":40},"100595750","phase-1-safety-and-efficacy-of-timod-sustained-release-implant-in-participants-with-glaucoma-or-ocular-hypertension-undergoing-cataract-surgery-100595750","NCT07036510","Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery","Early Feasibility Study to Evaluate the Safety and Efficacy of a New Timolol Sustained-Release Intraocular Implant (TimoD) in Participants With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Undergoing Cataract Surgery","Inclusion Criteria:\n\n* Capable of giving signed informed consent.\n* In good general and mental health without ongoing clinically significant abnormalities in medical history.\n* Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement.\n* Successful, uncomplicated cataract surgery\n\nExclusion Criteria:\n\n* Subjects with a history of hypersensitivity or contraindications to β- blockers.\n* Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure\n* Significant risks caused by washout of ocular hypotensive medications.\n* Clinically significant ocular pathology other than OHT, glaucoma and cataract.","40 Years",{"count":288,"type":21},42,[51,52],"The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.\n\nThe study is conducted in two stages. The first stage (Stage 1\u002FPhase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2\u002FPhase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.",[27,292],"Ocular Hypertension",[27,294,295,296,297,298],"Ocular hypertension","OHT","Cataract","Timolol","Lens diseases",{"date":223,"type":32},{"date":301,"type":32},"2025-06-12",{"date":303,"type":21},"2027-01",{"name":305,"class":39},"EyeD Pharma",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":40},"100578056","glaucoma-drop-aids-part-2-100578056","NCT06806332","Glaucoma Drop Aids Part 2","Inclusion Criteria:\n\n* Currently on the same topical ophthalmic medications for treatment of glaucoma for a minimum of two months\n* Patient of Boston University Eye Associates\n\nExclusion Criteria:\n\n* Changed glaucoma medications within the past 2 months",{"count":313,"type":21},80,[24],"Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.",[27,317],"Intraocular Pressure",[319,320],"Eye drop aid","Nanodropper","2026-07-26",{"date":323,"type":32},"2026-07-28",{"date":325,"type":21},"2026-10",{"date":205,"type":21},{"name":328,"class":88},"Boston Medical Center",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":40},"100614901","optimizing-graft-selection-in-glaucoma-surgery-a-comparative-study-of-sclera-pericardium-and-corneal-tissue-100614901","NCT07285616","Optimizing Graft Selection in Glaucoma Surgery: A Comparative Study of Sclera, Pericardium, and Corneal Tissue","Optimizing Graft Selection in Glaucoma Surgery","Inclusion Criteria:\n\n1. Age 18 years and older\n2. Patients selected for PreserFlo microshunt surgery and XEN stent alone or in combination with cataract surgery.\n3. Ability to comprehend the study procedures\n\nExclusion Criteria:\n\n1. Unwilling or unable to give consent\n2. Unable to come for scheduled post-operative visits\n3. Pregnant or nursing women\n4. Previous cyclodestructive procedures, scleral buckling procedures, or presence of silicone oil\n5. Conjunctival scarring precluding a glaucoma surgery superiorly\n6. Active iris neovascularization or active proliferative retinopathy\n7. Vitreous in the anterior chamber for which a vitrectomy is anticipated.\n8. Previous trabeculectomy, tube-shunt implantation, or surgeries that shunt aqueous outflow into the subconjunctival space","110 Years",{"count":338,"type":21},180,[24],"Glaucoma refers to a group of progressive optic neuropathies that lead to permanent vision loss. Glaucoma is the leading cause of irreversible blindness globally. In 2020, it was estimated to affect 76 million individuals worldwide, with projections indicating this number will rise to 111.8 million by 2040. In Canada, glaucoma affects an estimated 2.7-7.5% of individuals over the age of 50, contributing substantially to the national disease burden. This condition is linked to damage of the optic nerve due to elevated intraocular pressure (IOP; raised eye pressure), which results in the loss of retinal ganglion cells. Therefore, most of the treatments are guided towards reducing the IOP either via using laser, medications or surgery.\n\nGlaucoma surgery is typically reserved for cases where IOP remains uncontrolled while on maximum tolerated medical therapy and\u002For where glaucoma progression warrants surgery. The goal of many glaucoma surgeries is to divert aqueous humor from the anterior chamber to the subconjunctival space, therefore reducing intraocular pressure. The device used for this purpose are the PRESERFLO™ MicroShunt (Glaukos Corporation, Laguna Hills, CA, USA) (the documents will interchangeably use terms \"stent\" and \"shunt\" to refer to these devices in the text below). The device is implanted using the ab externo approach to channel fluid from the anterior chamber to the subconjunctival\u002Fsubtenon space. To reduce postoperative fibrosis and inhibit fibroblast activity that could obstruct flow and lead to device failure, 5-fluorouracil (5-FU) or mitomycin C (MMC) are administered. Additionally, a double-layered closure of conjunctiva and Tenon's is performed to minimize Tenon's migration and blockage of tenon the stents. Despite these measures, stent encapsulation and failure are still too common requiring revisions and bleb needling in 2-20% of cases within the first 12 months of follow-up.\n\nThis project will involve a series of studies evaluating graft selection in PreserFlo MicroShunt implantation, focusing on donor sclera, cornea, and pericardium as patch graft materials. First, the investigators will conduct a prospective, randomized study comparing clinical outcomes between these graft types. Outcomes of interest will include surgical success rates, post-operative hypotony, tube erosion, conjunctival complications, infection, and overall device longevity. Donor sclera has long been used as a patch graft in glaucoma drainage device surgery and is associated with low erosion rates and reliable long-term results. Corneal tissue is increasingly used due to its transparency and availability through eye banks, with demonstrated safety in ocular surface reconstruction and tube coverage. Pericardium is another durable, biocompatible option, historically applied in both cardiovascular and ocular surgery, and has shown effectiveness as a patch graft in glaucoma drainage implants. This comparison will extend to both primary implantation and revision surgeries, recognizing the high clinical relevance of graft performance in complex cases.\n\nBuilding on these results, the investigators will then perform a cost-effectiveness analysis of graft strategies, incorporating surgical time, post-operative management, complication rates, and need for re-operation. An economic model will be developed to evaluate costs and resource utilization associated with each material, providing valuable data for policy and surgical decision-making. Finally, the investigators will conduct a patient-reported outcome (PRO) study to assess patient comfort and satisfaction with different grafts. Surveys will evaluate domains such as foreign body sensation, cosmesis, and overall satisfaction at key time points (immediate post-operative period, 1 week, 3 weeks, and 3 months). These results will highlight the patient perspective, an often underrepresented but critical factor in surgical innovation.\n\nTogether, these studies will comprehensively assess graft selection from surgical, economic, and patient-centered perspectives, informing evidence-based practice in glaucoma care.",[27],[343,344,345],"PRESERFLO","surgery","MicroShunt","2026-07-23",{"date":348,"type":32},"2026-07-24",{"date":350,"type":21},"2026-09-15",{"date":352,"type":21},"2027-12-30",{"name":354,"class":88},"University of Alberta",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":379},"100510287","glaucoma-drainage-device-and-endothelial-cell-loss-compare-trial-100510287","NCT05924477","Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial","DECLARE","Inclusion Criteria:\n\n* Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure\n* Candidate for GDD implantation for ciliary sulcus and AC tube\n* Age greater than or equal to 18 years old\n\nExclusion Criteria:\n\n* Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant\n* Presence or history of Cypass Micro-Stent\n* Previous GDD, Xen Gel Stent or Preserflo MicroShunt removed less than 6 months before surgery\n* Presence of GDD implantation, Xen Gel Stent, of Preserflo MicroShunt\n* Previous trabeculectomy and\u002For minimally invasive glaucoma surgery within the past 6 months\n* AC intraocular lens\n* Presence of nanophthalmos, uncontrolled uveitis, silicone oil, Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure\n* Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits\n* No light perception vision in the study eye or fellow eye visual acuity \\\u003C 20\u002F200\n* Need for glaucoma surgery combined with other ocular procedures (i.e. corneal transplant, or retinal surgery) or anticipated need for additional ocular surgery",{"count":363,"type":21},226,[24],"Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.",[27],[103,248,368,369,370],"endothelial cell density","endothelial cell loss","intraocular pressure","2026-07-13",{"date":373,"type":32},"2026-07-14",{"date":375,"type":32},"2023-07-11",{"date":205,"type":21},{"name":378,"class":88},"University of Pennsylvania",8,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":122,"sex":17,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":40},"100625661","early-phase-1-optic-nerve-head-strain-in-non-glaucoma-subjects-100625661","NCT07425535","Optic Nerve Head Strain in Non-glaucoma Subjects","Inclusion Criteria:\n\n* Adults who have no history of OAG\n* Have an ocular examination by a glaucoma specialist with no indications of OAG\n* Have normal optical coherence tomography findings in the retinal nerve fiber layer.\n* Over age 30 will be included from\n* Both sexes\n* All ethnic groups.\n* Optic neuropathy.\n* Both suspects and those with glaucoma damage will be included.\n* When both eyes meet inclusion and exclusion criteria, both eyes will be included in the study and statistical methods will be used to account for correlations between eyes within the same individual.\n\nExclusion Criteria:\n\n* in whom sitting in an upright position is impossible due to physical disability\n* with ocular media opacity, corneal scarring, cataract or vitreous hemorrhage, that does not allow adequate imaging resolution.\n* in whom keeping the eyes open during the imaging procedure is not possible or uncomfortable.\n* who cannot perform home tonometry accurately at certification\n* who do not have reliable clinical Optical Coherence Tomography (OCT) testing.\n* with any form of glaucoma\n* with high myopia defined as refractive error \\> -8\n* with past keratorefractive surgery, corneal dystrophy, or corneal ectasia that would make self-tonometry measurements difficult to interpret\n* inability to understand English or with a language or hearing impairment","30 Years","90 Years",{"count":193,"type":21},[390],"EARLY_PHASE1","Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.",[27],[394,395,396,103],"optic nerve","biomechanical strain","normal eye","2026-07-10",{"date":371,"type":32},{"date":400,"type":32},"2026-06-24",{"date":402,"type":21},"2028-03-31",{"name":404,"class":88},"Johns Hopkins University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":414,"briefSummary":415,"conditions":416,"keywords":427,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":459,"locationsCount":40},"100619218","brain-stimulation-effects-on-orientation-and-mobility-skills-in-adults-with-vision-impairment-100619218","NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.",{"count":413,"type":21},20,[24],"This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[417,418,419,420,421,422,423,424,425,426,27],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence",[417,428,429,419,420,430,431,432,433,434,105,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","2026-07-02",{"date":455,"type":32},"2026-07-07",{"date":110,"type":21},{"date":458,"type":21},"2027-08-31",{"name":460,"class":88},"University of Waterloo",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":40},"100495044","ocular-blood-flow-imaging-for-glaucoma-assessment-100495044","NCT05726058","Ocular Blood Flow Imaging for Glaucoma Assessment","Inclusion Criteria:\n\n* Age 18 and older with binocular vision\n* Able to provide informed consent\n* Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria\n\nExclusion Criteria:\n\n* The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)\n* The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy\n* The subject has prior ocular disease other than glaucoma\n* The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye\n* The subject has more than 15 diopters of refractive error\n* The subject is a female who is pregnant or nursing\n* The subject has diabetes mellitus","88 Years",{"count":241,"type":21},[24],"The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.\n\nThe main question it aims to answer are:\n\n* Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?\n* Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?\n\nParticipants will be\n\n* measured for their blood pressure, heart rate, height, and weight\n* dilated with tropicamide\n* imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry\n* imaged using the XyCAM RI while inhaling 100% oxygen through a mask",[27],[103,473,474,475,476,477,478],"xycam","blood flow","imaging","ophthalmology","retinal blood flow","eye disease","2026-06-30",{"date":453,"type":32},{"date":482,"type":32},"2023-03-30",{"date":484,"type":21},"2028-04-30",{"name":138,"class":88},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":40},"100644778","world-sight-foundation-field-machine-wsffm-pilot-100644778","NCT07674069","World Sight Foundation Field Machine (WSFFM) Pilot","Clinical Testing Pilot of the World Sight Foundation Field Machine (WSFFM) in Glaucoma Patients - Comparison With Humphrey Visual Field Analyser","WSFFM","Inclusion Criteria:\n\n* \\- Patients attending glaucoma outpatient clinic\n* Patients requiring visual field testing, with plan for \"SITA-STANDARD\" HVF testing\n* Patients 18 years or older and of any gender\n* Patients capable of giving informed consent.\n\nExclusion Criteria:\n\n* \\- Patients not requiring visual field testing on that outpatient clinic attendance.\n* Patients requiring visual field testing, with plan for \"SITA-FAST\" or \"SITA-FASTER\" HVF testing.\n* Patients who do not attend their outpatient clinic appointment,\n* Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions).\n* Patients under the age of 18 years old.","99 Years",{"count":496,"type":21},100,[24],"The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.\n\nThe WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against \"the standard\" such that an idea of how well it works may be calculated.",[27],"2026-06-25",{"date":502,"type":32},"2026-06-29",{"date":504,"type":32},"2026-04-29",{"date":110,"type":21},{"name":507,"class":88},"Buckinghamshire Healthcare NHS Trust",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":535,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":259},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.",{"count":517,"type":21},500,[24],"This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[196,521,522,523,59,524,525,526,27,527,528,529,422,530,531,532,533,534],"Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[536,537,538,539,540,541,542,543,544,196,533,545,546,547,548,549,550,551,552,553,522,523,554,555,556,532,526,525,59,557,558,559,560,561,562,563,564,565,527,528,566,534],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":502,"type":32},{"date":569,"type":32},"2016-01",{"date":571,"type":21},"2028-07-31",{"name":573,"class":39},"MD Stem Cells",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":596},"100537189","study-of-oct-peripapillary-angiography-in-patients-with-advanced-glaucoma-100537189","NCT06274593","Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma","OGA","Inclusion Criteria:\n\n* Men and women aged 18 and over\n* Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital\n* mean visual field deficit (MD) \\>10dB\n\nExclusion Criteria:\n\n* Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR\u002FOBVR, OACR\u002FOBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...)\n* PPR (retinal PanPhotocoagulation), retinal cerclage\n* Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa)\n* AMD and other macular pathologies that can lead to central visual field deficits\n* Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract)\n* Loss of fixation point preventing visual field formation Pregnant or breast-feeding women\n* Protected adults under guardianship or curatorship\n* with unreliable visual fields (false positives and false negatives \\> 33%)\n* with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)",{"count":582,"type":21},50,"Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.\n\nTo date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.\n\nThe main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).",[27],[103,586,587],"OCTa","OCTrnfl","2026-06-23",{"date":400,"type":32},{"date":591,"type":32},"2024-04-27",{"date":593,"type":21},"2027-09",{"name":595,"class":88},"Nantes University Hospital",2,{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":22,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":4},"100643945","glaukomai-clinical-validation-of-an-ai-system-for-early-glaucoma-screening-100643945","NCT07668193","GlaukomAI: Clinical Validation of an AI System for Early Glaucoma Screening","GlaukomAI: Clinical Validation of an Artificial Intelligence-Based System for Early Glaucoma Screening and Diagnosis - A Case-Control Study and Referral Accuracy Assessment","GlaukomAIcare","Inclusion Criteria for all patients:\n\n* Age \\>18 years\n* Freely given informed consent obtained prior to study initiation\n* The participant has the capacity to understand and the willingness to follow study instructions and is likely to complete all required visits and procedures\n\nInclusion Criteria for glaucoma patients:\n\nPatients affected by any type of glaucoma (primary open-angle, primary angle-closure, secondary glaucoma) on pharmacological therapy\n\nInclusion Criteria for healthy controls:\n\n* Absence of ocular pathologies\n* IOP \\\u003C21 mmHg\n* Visual field and OCT within normal limits\n* Optic disc of normal appearance on clinical evaluation\n\nExclusion Criteria:\n\n* Presence of media opacities preventing the acquisition of adequate quality fundus imaging (e.g., advanced cataract, vitreous hemorrhage, severe corneal opacities)\n* Retinal or optic nerve pathologies that could confound the diagnosis (e.g., non-glaucomatous optic neuropathies (ischemic, inflammatory, compressive), moderate-to-severe diabetic retinopathy, advanced macular degeneration, retinal vascular occlusions)\n* Having undergone any ocular surgery in the past 3 months\n* Inability to cooperate with perimetric examination",{"count":606,"type":21},1200,[24],"Glaucoma is one of the leading causes of irreversible blindness worldwide. Early diagnosis is crucial to prevent vision loss, but current diagnostic pathways require multiple specialist visits and tests, leading to long waiting times and delayed diagnosis.\n\nThis study aims to evaluate the accuracy of GlaukomAI, an artificial intelligence (AI)-based software that analyzes fundus photographs of the eye to detect glaucoma at an early stage.\n\nThe study is conducted at IRCCS Fondazione G. B. Bietti (Rome, Italy) and is structured in two phases:\n\n* Phase 1 enrolls 200 participants (100 with diagnosed glaucoma and 100 healthy controls) to assess how accurately GlaukomAI can distinguish between glaucoma and healthy eyes, compared to the judgment of a panel of three expert glaucoma specialists.\n* Phase 2 enrolls 1,000 consecutive outpatients to evaluate whether GlaukomAI can correctly identify patients who need referral to a glaucoma specialist, and to compare its performance with that of non-specialist ophthalmologists.\n\nParticipants undergo a single study visit including standard ophthalmic examinations (visual acuity, eye pressure measurement, visual field test, OCT, and fundus photography). No investigational drugs or invasive procedures are involved.\n\nThe results of this study will provide evidence to support the integration of AI-based tools into routine glaucoma screening pathways, with the goal of reducing diagnostic delays and improving access to care.",[27],[27,611,612,613,614,615,616],"Artificial Intelligence","Fundus Photography","Glaucoma Screening","Early Diagnosis","Optic Nerve","GlaukomAI","2026-06-19",{"date":500,"type":32},{"date":620,"type":21},"2026-06",{"date":622,"type":21},"2028-05",{"name":624,"class":88},"Fondazione G.B. Bietti, IRCCS",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":4},"100644299","the-id2-a-smart-eye-drop-cap-monitor-for-eye-drop-adherence-100644299","NCT07664943","The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence","Inclusion Criteria:\n\n* Age ≥ 18\n* Taking at least one glaucoma drop daily\n* A history of poor adherence when taking glaucoma eye drops. This is determined as an answer of 80% or less for the following question: \"Over the past month, what percentage of your drops do you think you took correctly?\"\n* Owns a functioning smart phone with Bluetooth and cellular connectivity\n\nExclusion Criteria:\n\n* Advanced cognitive impairment\n* Current or expected pregnancy during the study.",{"count":496,"type":21},[24],"Most patients with glaucoma use eye drops to lower their intraocular pressure. However, poor adherence to prescribed eye drop regimens can lead to significant loss of vision-related quality of life. This study will test the iDrop Device (iD2), a device-on-cap electronic platform monitor designed to accurately track when a research participant removes an eye drop bottle cap, wirelessly communicate usage data to a database accessible to researchers, and send on-demand alerts when a medication is due. A device capable of tracking eye drop usage and sending dosage alerts will test the hypothesis that electronic reminders improve medication adherence and help research subjects improve their eye drop taking behavior. While our primary focus is on glaucoma adherence, this device could also benefit those with other chronic eye conditions requiring regular eye drop treatment, such as dry eye, corneal endothelial disease, eye infections, and uveitis.",[27,635],"Medication Adherence",[637,638,639,27,640],"iD2","Adherence","Medication","Device","2026-06-17",{"date":400,"type":32},{"date":644,"type":21},"2026-09-01",{"date":458,"type":21},{"name":647,"class":39},"Universal Adherence LLC",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":22,"phases":656,"briefSummary":657,"conditions":658,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":40},"100642917","phase-4-imaging-the-effects-of-netarsudil-rhopressa-on-the-trabecular-meshwork-in-glaucoma-and-ocular-hypertension-100642917","NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of ocular hypertension or open-angle glaucoma\n* Eye examination within the past year\n* For glaucoma subjects: structural (optic nerve and\u002For retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma\n* Best-corrected visual acuity of 20\u002F100 or better\n* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)\n* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)\n\nExclusion Criteria:\n\n* Known intolerance to netarsudil ophthalmic solution\n* Corneal scarring or active corneal disease that would interfere with imaging\n* Inability to tolerate gonioscopy procedures\n* Females of childbearing potential who are not using effective contraception or are not sterile\n* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion",{"count":582,"type":21},[243],"This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.",[27,292],"2026-06-09",{"date":661,"type":32},"2026-06-11",{"date":663,"type":32},"2026-06-05",{"date":665,"type":21},"2028-06",{"name":667,"class":88},"Indiana University",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":17,"minAge":675,"maxAge":4,"enrollmentInfo":676,"targetDuration":4,"studyType":22,"phases":678,"briefSummary":679,"conditions":680,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":683,"completionDateStruct":684,"leadSponsor":686,"locationsCount":4},"100643282","phase-1-evaluation-of-the-safety-efficacy-dose-response-of-the-bimatoprost-drug-ring-system-bim-drs-in-pseudophakic-patients-diagnosed-with-open-angle-glaucoma-or-ocular-hypertension-100643282","NCT07641296","Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension","Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, Efficacy, and Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Implanted With a Posterior Chamber Intraocular Lens (PC-IOL) and Diagnosed With Mild to Moderate Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension\n* Pseudophakic or planned removal of cataract\n* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease\n* History of incisional\u002Frefractive corneal surgery\n* Any glaucoma diagnosis other than OHT, open-angle, or pigmentary glaucoma\n* History of incisional glaucoma surgery\n* Other ocular diseases, pathology, or conditions","22 Years",{"count":677,"type":21},24,[51],"The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension. The main question it aims to answer is:\n\nDoes the BIM-DRS lower the pressure inside the eye to treat glaucoma or ocular hypertension?\n\nResearchers will compare two different doses of the BIM-DRS implanted either with a pre-existing commercially available monofocal intraocular lens (IOL) or concurrently with the SpyGlass IOL (IOL with silicone pads (no drug)).\n\nParticipants will:\n\n* Upon providing informed consent and successfully completing the screening visit, stop taking their IOP lowering medications in the eye to be treated.\n* Complete a baseline visit to further evaluate eligibility in the study eye.\n* Undergo surgery to implant the BIM-DRS (BIM-DRS and SpyGlass IOL for Cohorts 3 and 4). Only one eye of each participant will be treated.\n* Complete post-operative follow-up visits for evaluation at Day 1, Week 2, Week 6, Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 (last study visit).",[27,292],"2026-06-08",{"date":661,"type":32},{"date":225,"type":21},{"date":685,"type":21},"2030-03-31",{"name":687,"class":39},"SpyGlass Pharma, Inc."]